Full Breakdown
Ebola Vaccine Trial Begins Amid Congo’s Largest Outbreak
By Drooid · · How we work
Launch of the Tumaini Trial in Bunia
On October 23, the first participant received the Merck & Co. Ervebo vaccine in Bunia, the capital of Ituri province, marking the start of the “Tumaini” trial (Swahili for “hope”). The single-framework study will use a ring-vaccination strategy, immunising contacts deemed at high risk. Within weeks, the trial is expected to add two Bundibugyo-specific candidates: an Oxford ChAdOx1 adenoviral vector jab and a Moderna mRNA vaccine, both funded by the Coalition for Epidemic Preparedness Innovations (CEPI).
Outbreak Context
The Democratic Republic of Congo is experiencing its 17th Ebola outbreak, declared on May 15. The World Health Organization (WHO) has recorded 9,704 confirmed cases and 4,687 deaths, making it the country’s largest Ebola episode regardless of virus species. As of late October, WHO officials reported that only about 80 % of more than 30,000 contacts under follow-up had been reached in the latest 24-hour period, short of the 95 % target.
Vaccine Candidates and Trial Design
Ervebo, approved for the Zaire Ebola strain, is being evaluated for cross-protection against the Bundibugyo virus. Animal studies suggest it may reduce infection and mortality. The Oxford and Moderna candidates are purpose-built for Bundibugyo; serum produced by the Serum Institute of India has already generated over 600,000 dose equivalents of the Oxford drug substance in nine days. The trial will also enroll pregnant women and children aged 12 years and older, groups often excluded from early-phase studies.
Official Statements & Responses
He emphasized that rapid manufacturing could enable “millions of doses” if the trial succeeds. WHO chief Tedros Adhanom Ghebreyesus called the effort a source of hope, while WHO emergencies director Chikwe Ihekweazu highlighted the need for rigorous evidence to protect at-risk populations.
Verbatim Quotes
- “Tumaini will work closely with affected communities, health authorities and outbreak response partners to generate robust evidence on vaccine performance that could contribute to curtailing the epidemic, saving lives, and strengthening preparedness for future Bundibugyo outbreaks,” — CEPI
- “Bringing this trial into the Ebola response is an important step towards addressing the urgent needs of affected communities,” — Steve Ahuka-Mundeke, the DR Congo Ebola response incident manager